NCT07441460 2026-03-02A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerShanghai JMT-Bio Inc.Phase 3 Not yet recruiting1,800 enrolled
NCT07402473 2026-02-11EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast CancerRutgers, The State University of New JerseyPhase 2 Not yet recruiting50 enrolled
NCT07332533 2026-01-12A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerShanghai JMT-Bio Inc.Phase 2/3 Not yet recruiting490 enrolled
NCT07299890 2025-12-23An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerAnhui Provincial Cancer HospitalPhase 2 Not yet recruiting90 enrolled